How would anyone know how to value even after approval? What are we paying Advent. Are we merging the two entities. What will we charge per patient or dose? Will someone like Walgreens be distributing kits to store and ship the tumor and/or for the lysate?
They do not tell you enough to make a decision for valuation. I can only say as an all solid tumor vaccine we are probably way too cheap now.
In the grand scheme only having the full UK approval in 2023 is lousy but about the best we can expect this point.
Only getting a $2.50 SP with an approval shows how badly managed this company truly is. We’ve achieved higher SPs with far less.
It is important to remember that even after the October 5, 2020 let down on TLD release not what even pessimistic folks who still believe in the science would have really expected approval to take 3 years from the data lock announced that day. Anyone who said it would be 3 years would have been viciously attacked and yet here we are.
Sure if you focus on a cherry picked small number of late coming shareholders then yes they only waited maybe 3 years for a good payout. This CEO has poorly served the vast majority of those who invested during her tenure.
Also, the long term has arrived and accountability means NWBO does not get to keep reframing the meaning of that or kicking the real payoff endlessly into the future on one flimsy pretext or another.
Market Data 
Markets 
AI
